Narrow‐band UVB phototherapy and psoralen–ultraviolet A photochemotherapy in the treatment of cutaneous mastocytosis: a study in 20 patients

Abstract

This work provides evidence that both NB-UVB and PUVA represent a safe and useful second-line therapy of the cutaneous symptoms in mastocytosis.

Transient improvement of skin symptoms in an adult patient with pediatric‐onset cutaneous mastocytosis treated with interferon‐α

“…Therefore, the mainstays of treatment are antihistamines and adrenaline in autoinjector . Other therapeutic options in CM include narrow‐band UVB phototherapy, a photochemotherapy (UVA and psoralen), antileukotriens, and short‐term high‐potent glucocorticoids . Noteworthy, rupatadine efficacy in reduction in the severity of mediator‐related symptoms and quality of life improvement were proved in a randomized, double‐blind, placebo‐controlled trial .…”

“…15,16,18 Other therapeutic options in CM include narrow-band UVB phototherapy, a photochemotherapy (UVA and psoralen), antileukotriens, and short-term high-potent glucocorticoids. 15,16,20 Noteworthy, rupatadine efficacy in reduction in the severity of mediator-related symptoms and quality of life improvement were proved in a randomized, double-blind, placebo-controlled trial. 18 Nonsedating long-acting histamine H1R antagonists may be administered in increasing doses and up to four times daily in mastocytosis patients.…”

Efficacy of PUVA in Russian patients with mastocytosis: a case series and review of literature

“…Mastocytosis is characterized by excessive expansion and accumulation of clonal mast cells in one or more organs including skin . Several treatment options have been successfully used in treatment of skin symptoms associated with mastocytosis . Here, we retrospectively describe a case series of four adult patients with mastocytosis seen at our department over a 3‐year period (Table ).…”

“…All patients were instructed to wear protective spectacles during the treatment period; additional therapy was restricted to the use of emollients. The efficacy of the PUVA therapy was defined as improvement of pruritus, cutaneous lesions, and/or a decrease in the appearance of new lesions 3 and 6 months after the end of treatment as compared with pre‐PUVA evaluation . All patients gave their informed consent to participate in this study.…”

“…The beneficial effect of PUVA in patients with mastocytosis may be associated with (i) decrease in mast cell numbers and the subsequent release of histamine and (ii) reduction of pro‐inflammatory cytokines . Brazzelli and coauthors demonstrated decreased levels of tryptase in mastocytosis patients receiving PUVA . Some but not all papers described a marked decrease in mast cell numbers and histamine content of the lesional skin or the major metabolite of histamine in the urine, which were concomitant with relief of itch after PUVA but increased again after therapy had been stopped.…”